

Table S1. Autoimmune blistering diseases associated with idiopathic inflammatory myopathies: review of the literature

Case	Types of IIM	Age/Sex	Facial erythema	Gottron's papules	Creatine kinase (IU/l)	Muscle weakness	Autoantibody of IIM	Interval between IIM and ABD	Type of ABD	Treatment for IIM	Treatment for ABD
1	DM	65/M	+	+	NA	Mild	NA	2 weeks	BP	Oral PSL/AZA	Same as for DM
2	DM	70/M	+	+	3715	+	NA	9 months	BP	Oral PSL/MTX	Minoycline
3	DM	9/M	NA	NA	NA	NA	NA	2 years	PF	Oral mPSL/CSA	Oral mPSL/CY
4	DM	81/F	+	NA	183	+	NA	3 months	BP	Surgery for cancer	Topical steroids
5	DM	76/M	+	+	224	+	NA	4 years	PV	Oral PSL	Oral PSL/MTX
6	PM	47/F	NA	NA	NA	NA	Anti-Jo1	7 years	PV	Oral PSL/IVIG	Oral PSL/rituximab
Our case	DM	39/F	+	+	514	-	Anti-NXP-2	2 years	PF	Topical steroids	Topical steroids

ABD: autoimmune blistering disease; AZA: azathioprine; BP: bullous pemphigoid; CSA: cyclosporine A; CY: cyclophosphamide; DM: dermatomyositis; IIM: idiopathic inflammatory myopathies; IVIG: intravenous immunoglobulin; NA: not available; PF: pemphigus foliaceus; PM: polymyositis; PV: pemphigus vulgaris; PSL: prednisolone; MTX: methotrexate